Aug 14 (Reuters) - Eli Lilly and Co LLY.N:
SUPERLUMINAL MEDICINES ANNOUNCES COLLABORATION WITH ELI LILLY AND COMPANY TO ADVANCE SMALL MOLECULE THERAPEUTICS FOR CARDIOMETABOLIC DISEASES AND OBESITY
SUPERLUMINAL MEDICINES: ELIGIBLE TO RECEIVE UP TO $1.3 BILLION
SUPERLUMINAL MEDICINES: LILLY TO RECEIVE EXCLUSIVE RIGHTS TO DEVELOP & COMMERCIALIZE COMPOUNDS FROM COLLABORATION AFTER PREDEFINED CRITERIA IS MET